Larvol Delta - Aulos-Bioscience-Doses-First-Patient-in-Phase-2-Cohort-Evaluating-the-Combination-of-Avelumab-and-AU007-for-the-Treatment-of-NonSmall-Cell-Lung-Cancer

Proleukin low dose (aldesleukin low dose) - ILTOO

imneskibart (AU-007) - Aulos Biosci

Bavencio (avelumab) - EMD Serono

https://www.businesswire.com/news/home/20241127548812/en/Aulos-Bioscience-Doses-First-Patient-in-Phase-2-Cohort-Evaluating-the-Combination-of-Avelumab-and-AU-007-for-the-Treatment-of-Non-Small-Cell-Lung-Cancer

Nov 27, 2024

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next